IP 112Alternative Names: IP-112
Latest Information Update: 08 Sep 2016
At a glance
- Originator InnoPharma Inc
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Cancer
Most Recent Events
- 08 Sep 2016 Preregistration is ongoing in USA (Innopharma pipeline, September 2016)
- 25 Sep 2014 InnoPharma Inc has been acquired by Pfizer